Fennec Pharmaceuticals Inc (FENC)
4.72
+0.08
(+1.72%)
USD |
NASDAQ |
Nov 21, 16:00
4.72
0.00 (0.00%)
After-Hours: 20:00
Fennec Pharmaceuticals Enterprise Value: 119.06M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 119.06M |
| November 19, 2024 | 109.05M |
| November 18, 2024 | 102.46M |
| November 15, 2024 | 101.23M |
| November 14, 2024 | 112.48M |
| November 13, 2024 | 114.67M |
| November 12, 2024 | 107.81M |
| November 11, 2024 | 108.64M |
| November 08, 2024 | 109.46M |
| November 07, 2024 | 111.38M |
| November 06, 2024 | 127.57M |
| November 05, 2024 | 123.45M |
| November 04, 2024 | 119.29M |
| November 01, 2024 | 110.79M |
| October 31, 2024 | 111.34M |
| October 30, 2024 | 114.35M |
| October 29, 2024 | 123.13M |
| October 28, 2024 | 121.48M |
| October 25, 2024 | 108.05M |
| October 24, 2024 | 117.37M |
| October 23, 2024 | 114.08M |
| October 22, 2024 | 116.27M |
| October 21, 2024 | 119.56M |
| October 18, 2024 | 116.27M |
| October 17, 2024 | 119.29M |
| Date | Value |
|---|---|
| October 16, 2024 | 119.29M |
| October 15, 2024 | 119.29M |
| October 14, 2024 | 116.27M |
| October 11, 2024 | 112.98M |
| October 10, 2024 | 106.67M |
| October 09, 2024 | 108.59M |
| October 08, 2024 | 115.45M |
| October 07, 2024 | 117.09M |
| October 04, 2024 | 118.47M |
| October 03, 2024 | 115.72M |
| October 02, 2024 | 118.47M |
| October 01, 2024 | 123.95M |
| September 30, 2024 | 128.89M |
| September 27, 2024 | 131.02M |
| September 26, 2024 | 129.37M |
| September 25, 2024 | 121.44M |
| September 24, 2024 | 123.90M |
| September 23, 2024 | 128.55M |
| September 20, 2024 | 132.11M |
| September 19, 2024 | 133.48M |
| September 18, 2024 | 131.56M |
| September 17, 2024 | 132.66M |
| September 16, 2024 | 131.02M |
| September 13, 2024 | 138.40M |
| September 12, 2024 | 136.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
81.82M
Minimum
Dec 01 2021
323.34M
Maximum
Dec 28 2023
179.05M
Average
168.35M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.745M |
| Palatin Technologies Inc | 15.49M |
| iBio Inc | 9.932M |
| Theriva Biologics Inc | -12.74M |
| Oragenics Inc | 2.485M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.735M |
| Revenue (Quarterly) | 6.974M |
| Total Expenses (Quarterly) | 12.20M |
| EPS Diluted (Quarterly) | -0.21 |
| Gross Profit Margin (Quarterly) | 80.54% |
| Profit Margin (Quarterly) | -82.23% |
| Earnings Yield | -2.12% |
| Operating Earnings Yield | 1.19% |
| Normalized Earnings Yield | -2.082 |